1. Home
  2. REVB vs ONCO Comparison

REVB vs ONCO Comparison

Compare REVB & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.86

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$1.43

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REVB
ONCO
Founded
2020
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
4.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
REVB
ONCO
Price
$0.86
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
99.4K
53.7K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,223,751.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$1.42
52 Week High
$60.48
$179.35

Technical Indicators

Market Signals
Indicator
REVB
ONCO
Relative Strength Index (RSI) 36.34 27.29
Support Level $0.93 $1.54
Resistance Level $0.90 $1.66
Average True Range (ATR) 0.07 0.25
MACD -0.01 -0.08
Stochastic Oscillator 3.46 3.05

Price Performance

Historical Comparison
REVB
ONCO

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: